PATENT CLAIM ANALYSIS

Application Number: 16063622
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "469000"]

Abstract:
Two isoforms of thyroid receptor alpha (THRα1 and THRα2) have been found to be associated with the growth of cancer. Use of inhibitors of THRα1 (Formula I) and/or agonists of THRα2 (Formula II) in the treatment of such cancers is disclosed. Treatment of other disorders associated with such receptors is also contemplated, as is the use of diagnostic methods for predicting therapeutic outcomes based on the levels of expression of THRα1 and THRaα2 in a tissue sample.

Claim (Index 21):
A pharmaceutical composition for inhibiting THR\u03b11, or for treating a disease, disorder or condition that benefits from inhibition of THR\u03b11, comprising one or more compounds of Formula (I) as defined in any one of  claims 1  to  20 , or a pharmaceutically acceptable salt, and/or solvate thereof, and a pharmaceutically acceptable carrier and/or diluent.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 94.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15176812', '15539088', '14415061', '15712670', '15768257']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7820172204623275
- 35 USC 102 Novelty (BERT): 0.5107485618635635
- Combined Prediction Score: 0.754890354602451
- Mean Citation Score: 267.61987
- Max Citation Score: 280.80325
- Similarity Product: 191.6348966703117

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test